She Lei, Gong Xuan, Su Lin, Liu Chao
Department of Oncology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Hunan Key Laboratory of Pharmacogenetics, Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Front Neurol. 2023 Jan 9;13:1042888. doi: 10.3389/fneur.2022.1042888. eCollection 2022.
OBJECTIVE: Tumor-treating fields (TTFields) are a new therapeutic modality for patients with glioblastoma (GBM). However, studies on survival outcomes of TTFields are rarely reported in China. This study aimed to examine the clinical efficacy and safety of TTFields therapy for GBM in China. METHODS: A total of 93 patients with newly diagnosed GBM (ndGBM) and recurrent GBM (rGBM) were included in our study retrospectively. They were divided into two groups based on whether they used TTFields. Progression-free survival (PFS), overall survival (OS), and toxicities were assessed. RESULTS: Among the patients with ndGBM, there were 13 cases with TTFields and 39 cases with no TTFields. The median PFS was 15.3 [95% confidence interval (CI): 6.5-24.1] months and 10.6 (95% CI: 5.4-15.8) months in the two groups, respectively, with = 0.041. The median OS was 24.8 (95% CI: 6.8-42.8) months and 18.6 (95% CI: 11.4-25.8) months, respectively, with = 0.368. Patients with subtotal resection (STR) who used TTFields had a better PFS than those who did not ( = 0.003). Among the patients with rGBM, there were 13 cases with TTFields and 28 cases with no TTFields. The median PFS in the two groups was 8.4 (95% CI: 1.7-15.2) months and 8.0 (95% CI: 5.8-10.2) months in the two groups, respectively, with = 0.265. The median OS was 10.6 (95% CI: 4.8-16.4) months and 13.3 (95% CI: 11.0-15.6) months, respectively, with = 0.655. A total of 21 patients (21/26, 80.8%) with TTFields developed dermatological adverse events (dAEs). All the dAEs could be resolved or controlled. CONCLUSION: TTFields therapy is a safe and effective treatment for ndGBM, especially in patients with STR. However, it may not improve survival in patients with rGBM.
目的：肿瘤治疗电场（TTFields）是胶质母细胞瘤（GBM）患者的一种新治疗方式。然而，中国关于TTFields生存结局的研究报道较少。本研究旨在探讨TTFields治疗中国GBM患者的临床疗效和安全性。 方法：本研究回顾性纳入了93例新诊断GBM（ndGBM）和复发性GBM（rGBM）患者。根据是否使用TTFields将他们分为两组。评估无进展生存期（PFS）、总生存期（OS）和毒性。 结果：在ndGBM患者中，使用TTFields的有13例，未使用的有39例。两组的中位PFS分别为15.3[95%置信区间（CI）：6.5 - 24.1]个月和10.6（95%CI：5.4 - 15.8）个月，P = 0.041。中位OS分别为24.8（95%CI：6.8 - 42.8）个月和18.6（95%CI：11.4 - 25.8）个月，P = 0.368。接受次全切除（STR）且使用TTFields的患者PFS优于未使用者（P = 0.003）。在rGBM患者中，使用TTFields的有13例，未使用的有28例。两组的中位PFS分别为8.4（95%CI：1.7 - 15.2）个月和8.0（95%CI：5.8 - 10.2）个月，P = 0.265。中位OS分别为10.6（95%CI：4.8 - 16.4）个月和13.3（95%CI：11.0 - 15.6）个月，P = 0.655。共有21例（21/26，80.8%）使用TTFields的患者发生了皮肤不良事件（dAEs）。所有dAEs均可缓解或得到控制。 结论：TTFields治疗对ndGBM是一种安全有效的治疗方法，尤其是对STR患者。然而，它可能无法改善rGBM患者的生存期。
Neurooncol Pract. 2021-4-20
Oncologist. 2025-2-6
J Natl Compr Canc Netw. 2020-11-2
J Cancer Res Clin Oncol. 2019-12-11
Zotero 插件
